GlobeNewswireOCT 303 min read$LIMN

Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation

LA PALMA, Calif., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Liminatus Pharma, Inc. ( NASDAQ: LIMN ) , a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding ( MOU ) with Capital Trust Group ...

Original reporting

GlobeNewswire · Liminatus Pharma Inc.

Published Oct 30, 2025, 2:04 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Oct 30, 2025, 3:00 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation — source image — Source · www.globenewswire.com

Decision brief

The 30-second read

$LIMNBullishMed

Why it matters

The partnership with Capital Trust Group provides significant capital and strategic support, potentially accelerating clinical development and commercialization.

Market read

The news is relevant for biotech investors, indicating potential growth and increased investor confidence in Liminatus Pharma.

What to watch

Execution risk of strategic cooperation and market conditions could negate positive effects.

Timing: Immediate to short-term (next 1-3 months)

Background

Liminatus Pharma is developing next-generation CD47-blockade therapies, aiming to advance immuno-oncology treatments.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$LIMNBullishMedium confidence

Context

Primary focus due to recent strategic investment news.

Expected impact

Moderate upward movement over the next 1-3 months.

Evidence & confidence

The strategic partnership and capital infusion are favorable signals; however, the impact depends on execution and broader market conditions.

Market effects

Sector

Potential uplift in biotech and immuno-oncology sectors due to increased investor interest.

Regional

Limited regional impact; primarily US-based company.

Global

Moderate; reflects global investor interest in biotech collaborations.

Counterpoint

What could challenge this read

The strategic investment may lead to dilution or overvaluation, posing risks for existing shareholders.

Key entities

Company
Liminatus Pharma, Inc.
A clinical-stage immuno-oncology company focusing on CD47 therapies.
Financial Institution
Capital Trust Group
A group providing strategic investment and financial support.

Read at source ← All news

AUG 24

$LIMNMed

Liminatus Partners with Korean Firm for CAR

Liminatus Pharma partners with Synex Consulting to advance its CAR-T cell therapy in South Korea. The Ministry of Food and Drug Safety authorized a Phase 1/2a clinical study. Liminatus went public via a SPAC last year. Shares are down 8.2% to $4.73, with a $6.4M market cap.

ocbj.com2 min

JUL 6

$LIMNMed

Liminatus Pharma, Inc. (LIMN): Completion of Acquisition or Disposition of Assets

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 tm2619730d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AMENDED AND RESTATED MERGER AGREEMENT dated June 29, 2026 by and among InnocsAI LLC, Delaware limited liability company (the “ Company ”), NamChul Jung, as the Members’ Representative (the “ NamChul Jung ”), and Liminatus Pha

SEC EDGAR 8-K3 min

JUL 2

$LIMNMedAI 8/10

Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Sessio

Liminatus Pharma (NASDAQ:LIMN) shares rose 30.49% to $0.15 in after-hours after the company amended and restated its merger agreement with InnocsAI LLC. The revised terms aim to let the deal close before shareholder approval, expected Thursday, with consideration valued at $0.20 per share plus contingent value rights.

benzinga.com3 min

JUL 1

$LIMNMedAI 8/10

Liminatus Pharma Amends Merger Agreement With InnocsAI To Expand Oncology Pipeline

Liminatus Pharma (LIMN) amended its merger agreement with InnocsAI LLC to expand its oncology pipeline. The deal is now expected to close July 2, 2026, before stockholder approval. InnocsAI holders will receive Liminatus common stock and newly designated non-voting convertible preferred issued at $0.20/share, implying ~$320M value, plus CVRs on 20% of future net proceeds.

rttnews.com4 min

AUG 28

$MAIRMedAI 8/10

Billionaire Tycoon Ernesto Bertarelli Buys $219 Million in Madison Air Solutions Shares. What Does This Mean for Investors?

Billionaire Ernesto Bertarelli indirectly purchased 8.8 million shares of Madison Air Solutions (MAIR) at $24.97 per share, totaling $219 million. The acquisition was made through K.C. Armada, LP, bringing his indirect ownership to 11% of the company. MAIR's stock closed at $28.51, a 14% premium over the purchase price. The company has a market cap of $14.3 billion and expects 18% revenue growth this fiscal year.

fool.com2 min